TY - JOUR
T1 - Increased choline kinase activity in human breast carcinomas
T2 - Clinical evidence for a potential novel antitumor strategy
AU - De Molina, Ana Ramírez
AU - Gutiérrez, Ruth
AU - Ramos, Maria Angeles
AU - Silva, José María
AU - Silva, Javier
AU - Bonilla, Félix
AU - Sá Nchez, José Javier
AU - Lacal, Juan Carlos
N1 - Funding Information:
We gratefully thank Dr S Yamashita for kindly providing us with the cDNA encoding mammalian ChoK. This work was supported by Grant 2FD1997-1569 from CICYT, Grant 99/0817 from FIS, Grant 08.1/0045.1/98 from Consejerṍ a de Educación of Comunidad de Madrid, and a special Grant from Roche Diagnostics GmbH, Pharma Research Penzberg (Alemania). We appreciate the critical reading of the manuscript by Miguel Martin and Ramón Colomer. A. Ramirez de Molina is a fellow from Fondo de Investigación Sanitaria (Instituto de Salud Carlos III), grant BEFI 99/9125 (Ref. CPC/CLC).
PY - 2002/6/20
Y1 - 2002/6/20
N2 - Choline kinase (ChoK) and its product, phosphocholine (PCho), have been implicated in human carcinogenesis. Inhibition of this enzyme has been shown to be an efficient antitumor strategy in vivo. The aim of this study was to assess the relationship between the regulation of ChoK and clinical features in patients with breast cancer. To that end, normal and tumoral tissues from 53 patients with breast carcinomas were analysed for ChoK activity and expression, and compared to some clinical parameters. We report a relevant increase in ChoK activity in 38.5% of the tumoral tissues analysed when compared to the normal levels in healthy tissues. Furthermore, some clinical features were found significant versus ChoK status. First, an association of choline enzymatic activity with histological tumor grade was observed (P<0.001). In addition, increased ChoK activity was also associated with ER-negative breast carcinomas (P=0.037). A significant association between ChoK overexpression and both high histologic tumor grade (P=0.017) and ER-negative tumors (P=0.003) was found. Finally, ChoK overexpression was found in 17% of the samples and all corresponded with those that display the highest increase in ChoK activity (P<0.001). Here we provide evidence that ChoK may be related to the development of human breast cancer, suggesting that this finding may constitute the basis for the development of a novel antitumoral strategy for these patients.
AB - Choline kinase (ChoK) and its product, phosphocholine (PCho), have been implicated in human carcinogenesis. Inhibition of this enzyme has been shown to be an efficient antitumor strategy in vivo. The aim of this study was to assess the relationship between the regulation of ChoK and clinical features in patients with breast cancer. To that end, normal and tumoral tissues from 53 patients with breast carcinomas were analysed for ChoK activity and expression, and compared to some clinical parameters. We report a relevant increase in ChoK activity in 38.5% of the tumoral tissues analysed when compared to the normal levels in healthy tissues. Furthermore, some clinical features were found significant versus ChoK status. First, an association of choline enzymatic activity with histological tumor grade was observed (P<0.001). In addition, increased ChoK activity was also associated with ER-negative breast carcinomas (P=0.037). A significant association between ChoK overexpression and both high histologic tumor grade (P=0.017) and ER-negative tumors (P=0.003) was found. Finally, ChoK overexpression was found in 17% of the samples and all corresponded with those that display the highest increase in ChoK activity (P<0.001). Here we provide evidence that ChoK may be related to the development of human breast cancer, suggesting that this finding may constitute the basis for the development of a novel antitumoral strategy for these patients.
KW - Anti-cancer drugs
KW - Breast carcinomas
KW - Choline kinase
KW - Estrogen receptors
UR - http://www.scopus.com/inward/record.url?scp=0037142610&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1205556
DO - 10.1038/sj.onc.1205556
M3 - Article
C2 - 12082619
AN - SCOPUS:0037142610
SN - 0950-9232
VL - 21
SP - 4317
EP - 4322
JO - Oncogene
JF - Oncogene
IS - 27
ER -